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A B S T R A C T
Recent evidence indicates that psilocybin with psychological support may be effective for treating depression.
Some studies have found that patients with depression show heightened amygdala responses to fearful faces
and there is reliable evidence that treatment with SSRIs attenuates amygdala responses (Ma, 2015). We hy-
pothesised that amygdala responses to emotional faces would be altered post-treatment with psilocybin. In
this open-label study, 20 individuals diagnosed with moderate to severe, treatment-resistant depression, un-
derwent two separate dosing sessions with psilocybin. Psychological support was provided before, during and
after these sessions and 19 completed fMRI scans one week prior to the first session and one day after the
second and last. Neutral, fearful and happy faces were presented in the scanner and analyses focused on the
amygdala. Group results revealed rapid and enduring improvements in depressive symptoms post psilocybin.
Increased responses to fearful and happy faces were observed in the right amygdala post-treatment, and right
amygdala increases to fearful versus neutral faces were predictive of clinical improvements at 1-week. Psilo-
cybin with psychological support was associated with increased amygdala responses to emotional stimuli, an
opposite effect to previous findings with SSRIs. This suggests fundamental differences in these treatments’
therapeutic actions, with SSRIs mitigating negative emotions and psilocybin allowing patients to confront and
work through them. Based on the present results, we propose that psilocybin with psychological support is a
treatment approach that potentially revives emotional responsiveness in depression, enabling patients to re-
connect with their emotions.
Trial registration
ISRCTN, number ISRCTN14426797.
© 2017.
1. Introduction
Psychedelic therapy is a re-emerging paradigm in psychiatry (dos
Santos et al., 2016; Mithoefer et al., 2016). Unlike other psychophar-
macological treatment models that seek to medicate patients on a
chronic basis, the psychedelic model seeks to treat core psycholog-
ical issues via a small number of profound and potentially transfor-
mative psychological experiences (Pahnke et al., 1970; Watts et al.,
2017). Our recent open-label study of psilocybin with psychologi-
cal support for treatment-resistant depression (TRD) yielded promis-
ing results, with all patients showing some reduction in depressive
symptoms at 1 week and half meeting criteria for remission at 3
weeks (Carhart-Harris et al., 2017). Furthermore, other clinical stud-
ies with psilocybin have found reductions in anxiety and depres-
sive symptoms after
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psilocybin with psychological support (Griffiths et al., 2016; Ross et
al., 2016).
Psilocybin, a classic psychedelic and non-selective serotonin 2A
receptor (5-HT2AR) agonist, was discovered and marketed in the
1950s and 60s (Hofmann et al., 1958). After much early enthusi-
asm about the therapeutic potential of psychedelics (Grinspoon and
Bakalar, 1979; Rucker et al., 2016), a politically-led about-turn in the
mid-1960s and early 1970s effectively ended all research with these
drugs, and it has only been in the last 10–15 years that clinical re-
searchers have begun to work with them again. During this renascent
period, impressive results have been found for the treatment of depres-
sion (Carhart-Harris et al., 2016; Osório et al., 2015), end of life anxi-
ety (Gasser et al., 2014a; Griffiths et al., 2016; Grob et al., 2011; Ross
et al., 2016), obsessive compulsive disorder (Moreno et al., 2006) and
addiction (Bogenschutz and Johnson, 2016).
The amygdala has previously been implicated in the pathophys-
iology of depression (Drevets et al., 1992) as well as the action of
some antidepressants (Ma, 2015) and psychedelics (Kraehenmann et
al., 2015; Spain et al., 2015). The amygdala is a complex subcortical
https://doi.org/10.1016/j.neuropharm.2017.12.041
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structure that is sensitive to emotional stimuli (Janak and Tye, 2015;
Sergerie et al., 2008). Functional MRI studies of untreated clinically
depressed patients have found amygdala hyper-sensitivity to negative
emotional stimuli (Drevets et al., 1992; Ma, 2015), and treatment with
SSRIs has been found to attenuate this; both with chronic SSRI-use as
well as early in treatment, prior to the appearance of clinical improve-
ments (Godlewska et al., 2012).
Here, we sought to explore the antidepressant action of psilocy-
bin on amygdala responses to emotional faces using a functional mag-
netic resonance imaging (fMRI) paradigm that has been well-vali-
dated in the context of SSRI-based treatments for depression (Ma,
2015). Patients underwent balanced versions of an emotional faces
paradigm before and one-day after treatment with psilocybin. Psilo-
cybin has been found to be associated with improved mood in the
sub-acute period days after exposure (Majić et al., 2015). We there-
fore predicted that amygdala responses to emotional faces would be
altered post-treatment and that this might relate to changes in depres-
sion severity. We were particularly interested in the fearful versus neu-
tral faces contrast, due to previous findings of reduced amygdala re-
sponses to negative emotional stimuli with SSRIs (Ma, 2015). We also
predicted that the nature of the acute psychological experience under
psilocybin would relate to the post-treatment changes in amygdala re-
sponses.
2. Material and methods
This trial received a favourable opinion from the National Re-
search Ethics Service London—West London, was sponsored and ap-
proved by Imperial College London and by the UK MHRA. All par-
ticipants provided written informed consent.
2.1. Design
The full study procedure is reported in (Carhart-Harris et al., 2016).
The inclusion criteria were major depression of a moderate to se-
vere degree (16 + on the 21-item Hamilton Depression Rating scale
[HAM-D]), and no improvement despite two adequate courses of an-
tidepressant treatment (6 weeks minimum, each). The patients were
asked to be antidepressants-free for at least two weeks before the
study. Exclusion criteria were: current or previously diagnosed psy-
chotic disorder; immediate family member with a diagnosed psychotic
disorder; medically significant condition rendering unsuitability for
the study; history of serious suicide attempts (requiring hospitalisa-
tion); history of mania; blood or needle phobia; positive pregnancy
test at screening or during the study; and current drug or alcohol
dependence. Psilocybin was obtained from THC-pharm (Frankfurt,
Germany) and formulated into the investigational medicinal product
(5 mg psilocybin in size 0 capsules). A week before the psilocybin
session, patients attended a preparatory session with their therapists.
In this session patients were invited to talk openly about their per-
sonal history (including thoughts on the origins of their depression),
discussed psilocybin's psychological effects, and simulated aspects of
the dosing session itself, such as listening to a sample of the ses-
sion music while wearing eyeshades. The preparatory session typi-
cally lasted for 4 h, with lunch and breaks provided. The sessions
took place in a decorated room with a relaxed atmosphere. The ra-
tionale behind the first low dose session was to prepare patients to
the high dose, build rapport with the therapists, and test their willing-
ness to “let-go”. Twenty Patients underwent two psilocybin-assisted
therapy sessions, a week apart. The first involved a low (test) dose of
psilocybin (10 mg, p.o.), and the second, a higher (therapeutic) dose
(25 mg, p.o). The high dose is comparable to the effective clinical
psilocybin doses used in Griffiths et al. (2016) (22 or 30 mg/70kg)
and Ross et al. (2016) (0.3mg/kg). The low dose produces attenuated
but still discernible perceptual and subjective effects (Griffiths et al.,
2011). The rationale behind the low dose session was as a prepara-
tion for the high dose session, providing an opportunity to build rap-
port with the therapists and help to reduce anxiety for the high dose
session. Post capsule ingestion, patients lay with eyes closed while
listening to music. Two therapists adopted a non-directive, support-
ive approach. Baseline fMRI scanning was conducted prior to any
psychological or pharmacological interventions and the post treatment
fMRI scan occurred the morning after the high dose psilocybin ses-
sion, prior to any psychological integration work. Scanning sessions
took place at identical times of the day (i.e. 10:00am). Out of the ini-
tial 20 patients, 19 completed both scanning sessions (6 females; mean
age = 44.7± 10.9; 27 to 64).
2.2. Anatomical scans
Imaging was performed on a 3T Siemens Tim Trio using a
12-channel head coil at Imanova, London, UK. Anatomical images
were acquired using the ADNI-GO (Jack et al., 2008) recommended
MPRAGE parameters (1 mm isotropic voxels, TR = 2300ms,
TE = 2.98ms, 160 sagittal slices, 256× 256 in-plane FOV, flip an-
gle = 9°, bandwidth = 240Hz/pixel, GRAPPA acceleration = 2).
2.3. BOLD fMRI emotional faces images task
T2*-weighted echo-planar images (EPI) were acquired for the
functional scan using 3 mm isotropic voxels, TR = 2000ms,
TE = 31ms, 36 axial slices, 192 mm in-plane FOV, flip angle = 80°,
bandwidth = 2298 Hz/pixel, GRAPPA acceleration = 2, number of
volumes = 245. Patients used a mirror mounted on the head-coil to
view a screen mounted in the rear of the scanner bore, where visual
stimuli were back-projected through a wave-guide in the rear wall of
the scanner room. The emotional faces task was a block-design task
lasting 8 min. Patients were shown faces with either fearful, happy, or
neutral expressions, selected from the Karolinska Directed Emotional
Faces set (Goeleven et al., 2008). An equal number of male and female
faces were selected for the task. Each face was presented on screen
for 3s, and five faces of the same expression were presented in each
15s block. Rest blocks (also 15s) were also included, and there were 8
repetitions of each block type, presented in a pseudo-random sequence
(32 blocks in total). Two versions of the task were used with one pre-
senting blocks in the reverse order to the other. Order of the task ver-
sions on each scanning visit was counter-balanced across patients. Pa-
tients passively viewed the faces but were instructed to press a single
button with their thumb with the presentation of each new face, to con-
firm that they were paying attention to the stimuli.
2.4. BOLD pre-processing
Four different but complementary imaging software packages were
used to analyse the fMRI data. Specifically, FMRIB Software Li-
brary (FSL) (Smith et al., 2004), AFNI (Cox, 1996), Freesurfer (Dale
et al., 1999) and Advanced Normalization Tools (ANTS) (Avants et
al., 2009) were used. The following pre-processing stages were per-
formed: 1) motion correction (3dvolreg, AFNI) by registering each
volume to the volume most similar, in the least squares sense, to all
others (in-house code); 2) brain extraction (BET, FSL); 3) rigid body
registration to anatomical scans (BBR, FSL); 4) non-linear registra-
tion to 2mm MNI brain (Symmetric Normalization (SyN), ANTS);
5) scrubbing (Power et al., 2012) – using a framewise displacement
(FD) threshold of 0.90mm, which is a recommended threshold for
task fMRI (Siegel et al., 2014). No significant differ
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ence in head movement (mean FD) was found between before and
after therapy scans (0.243 mm ± 0.116 and 0.248mm ± 0.12, respec-
tively, p= .815). The mean percentage of scrubbed volumes across
subjects (n = 19) for the before scan was 2.3% ± 3.7 (range = 0–15.1%),
and for the after scan, it was 2.3% ± 3.3 (range = 0–11.8%). Scrubbed
volumes were replaced with the mean of the surrounding volumes;
6) spatial smoothing (FWHM) of 6mm (3dBlurInMask, AFNI); 7)
high-pass filter of 0.01Hz; 8) regressing out 6 motion-related nuisance
regressors (3 translations, 3 rotations, high-pass filtered with the same
0.01Hz filter).
2.5. ROI analysis
We used two different approaches to investigate changes of amyg-
dala activity. The first involved calculating mean amygdala signal of
left and right amygdala ROIs. The second involved voxelwise analy-
sis within a bilateral amygdala mask (Harvard-Oxford atlas, proba-
bility > 50%). For both approaches, a standard General Linear Model
(GLM) was used for the first analysis step, as implemented in the
FEAT module in FSL. Regressors derived from the onset times of
each stimulus condition were convolved with a Gamma function in
order to simulate the Haemodynamic Response Function (HRF).
Pre-whitening (FILM) was applied to correct for autocorrelations.
Contrasts were defined that isolated activity related to each stimu-
lus condition (fearful, happy, neutral) relative to the baseline, and
also compared between two stimulus conditions, as appropriate (fear-
ful > neutral and happy > neutral) (Five contrasts in total). Two-tailed
t-tests were performed to compare before versus after treatment (be-
fore any intervention and after the high dose) BOLD responses for
the mean ROI analysis and mixed-effects GLM (FLAME-1+2) for
the voxelwise analysis. A statistical threshold of Z > 2.3, (cluster-cor-
rected for multiple comparisons with p < .05) was used for all voxel-
wise analyses. A further voxelwise exploratory analysis was carried
out on the whole brain.
2.6. Relationship with clinical outcomes
The relationships with clinical outcomes were observed using vox-
elwise analysis within a right amygdala mask (only the right amyg-
dala was chosen based on the first level results). For each subject, a
fixed-effects analysis was conducted to calculate the difference be-
tween before versus after therapy (before any intervention and after
the high dose). A higher level mixed-effects GLM (FLAME 1 + 2)
was used with the relevant clinical outcome as a regressor of in-
terest. In order to avoid multiple comparisons, we chose only two
clinical outcomes of interest: 1) the self-rated Beck Depression In-
ventory (BDI) 1-week after therapy, criterion for remission was ≤ 9,
which is based on a cut-off by Beck et al. (1988), and criterion for
treatment response was 50% reduction from baseline – a consensus
which has been validated by Riedel et al. (2010); and 2) treatment re-
sponse (50% reduction) based on in-scanner ‘state’ rating (0–20) of
depressed mood (baseline (before treatment) compared with one-day
after treatment). The in-scanner ratings were taken immediately after
the faces task and thus, sample the depressed ‘state’ (compared to the
BDI which asks about the last two weeks). After viewing the imag-
ing results we decided to use post-hoc the Quick Inventory of Depres-
sive Symptomatology (QIDS) (Rush et al., 2003) at 1-day (concerning
only the time since the therapy session), 1-week, 2-weeks, 3-weeks,
and 5-weeks post-treatment. We chose to use QIDS as an extra scale
to measure depression and to strengthen the relationship between
changes in the amygdala and depression. QIDS was measured in
more time pointes then BDI and therefore allowed us to observe how
changes in the amygdala predict clinical outcomes in different time
points. Furthermore, as reduced anxiety was an important clinical out-
come in other psilocybin studies (Griffiths et al., 2016; Ross et al.,
2016), we looked also at relationship between anxiety and amyg-
dala changes. Anxiety was measured at the day of the scan using the
in-scanner rating, and 1 week after the scan using State-Trait Anxiety
Inventory (STAI) (Spielberger et al., 1970).
3. Results
3.1. ROI analysis
Increased post-treatment BOLD responses were observed in the
right amygdala for fearful (p= .001) and happy faces (p= .022), with
a trend effect for neutral faces (p = .066) (Fig. 1). After correcting for
10 tests (5 contrasts X 2 ROIs), only the increased responses to fearful
faces remained significant. No significant result was observed in the
left amygdala (p= .11, p= .95 and p= .2, for fearful, happy and neutral
faces, respectively). Voxelwise analysis revealed significantly greater
responses in the right amygdala post-treatment for four contrasts: fear-
ful, happy and neutral faces, plus fearful > neutral faces (Fig. 2). In-
creases were in a consistent location of the right amygdala.
3.2. Whole brain analysis
Whole brain analysis (Fig. 3) revealed that for the fearful, happy
and neutral contrasts, in addition to increased BOLD responses in the
amygdala, there were also increased responses in other visual areas.
Whole brain increases for fearful > neutral were more limited to right
amygdala and right middle temporal gyrus however.
3.3. Relationship with clinical outcomes
The a priori defined primary imaging outcome of interest was al-
tered amygdala responses for fearful > neutral faces for after vs before
therapy. We hypothesized that the increased amygdala responsive-
ness was related to: 1) changes in state depression, measured via in-
Fig. 1. Mean Z values of BOLD activation in right amygdala for different stimuli condi-
tions, before and after psychedelic-assisted therapy. Increased amygdala responsivity is
observed for both fearful and happy faces. No significant result was found for left amyg-
dala. Error Bars = Standard Deviation * p < .05 (2-tail t-test, uncorrected) **p < .05
(2-tail t-test, Bonferonni correction for 10 comparisons (5 contrasts X 2 ROIs).
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Fig. 2. Voxelwise increases within right amygdala mask (after > before therapy). Significant clusters within right amygdala that showed increased responsivity after therapy. Cluster
size and Max point are presented as well. Note that for all four contrasts the cluster is located in a similar location. All results are cluster corrected (z > 2.3, p< .05).
Fig. 3. Whole brain voxelwise changes. Significant clusters that showed increased (hot colours) or decreased (cool colours) responsivity after therapy (cluster corrected, z > 2.3,
p< .05).
scanner ratings of depressed mood, and 2) changes in trait depression,
measured via BDI scores at baseline and 1-week after therapy. Other
exploratory relationships are shown in Table 1.
3.3.1. In-scanner ratings
State depression (0–20) was rated by patients directly after their
8-min faces scan. One day after psilocybin, 15 of 19 TRD patients
(79%) showed a clinically meaningful response (in-scanner rating;
reduction from baseline ≥ 50%) and treatment-response was signif-
icantly related to increased amygdala responses to fearful > neutral
faces, with greater activations relating to better outcomes (Table 1).
Response rates in state anxiety (42.1%) did not relate to changes in
amygdala.
3.3.2. BDI
Change (10.2 ± 5.3), response (63.2%) and remission (57.9%) in
BDI scores at 1-week were significantly related to post-treatment in-
creases in amygdala responses to fearful > neutral faces, with greater
activations relating to better outcomes (Table 1).
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Table 1
Relationship between BOLD changes (after > before therapy; fearful > neutral) within the right amygdala and clinical outcomes. To avoid multiple comparisons, we hypothesized that
amygdala changes would be related to two main clinical outcomes BDI at 1 week and in-scanner depression ratings. Other comparisons should be considered exploratory (QIDS,
STAI and in-scanner state anxiety). The “Type of score” column describes how the test was done: Remission (BDI≤9) and Response (>50% reduction) were used to split the group
for remitters/non-remitters or responders/non-responders. The differences between responders and non-responders and remitters and non-remitters are presented in the Max column
which describe the z score in the Max voxel of difference, and the z scores of these categories separately are also reported in separate columns for the same voxel as in Max. The
“Type of score” “Change” is the difference in the rating for After-Before. The “Change” in BDI and the change in amygdala response were entered to a GLM. Note that clusters close
to MNI_152 coordinates (x,y,z) of 18,0,-20 are reliable as they survived cluster correction for few of the clinical outcomes. Furthermore, note that the significant clusters had reduced
response for non-responders and non-remitters and enhanced response for responders and remitters. Real cluster sizes may be larger as the clusters in this table are constrained by the
amygdala mask. N = 19.
Rating
Time
point Type of score
Volume
(mm3)
Difference Max
(z)
Non-resposnders or non-
remitters (z)
Responders or
Remitters (z)
MNI_152
Coordinates
Signif-
cane
x y z
In-scanner
depression
1 day Response (n = 10) 24 2.47 −2.18 1.5 18 0 −18 *
BDI 1 week Remission
(n = 11)
160 3.3 −2.25 2.42 22 0 −22 **
Response (n = 12) 144 2.98 −2.48 1.86 18 0 −22 **
Change
(10.2 ± 5.3)
56 3 – – 18 0 −20 *
QIDS 1 day Response (n = 13) 192 3 −2.5 1.75 18 0 −20 **
1 week Response (n = 12) 104 2.9 −2.34 1.83 18 0 −20 *
2 weeks Response (n = 11) – – – – – – – –
3 weeks Response (n = 12) 104 2.9 −2.34 1.83 18 0 −20 *
5 weeks Response (n = 9) – – – – – – – –
In-Scanner
anxiety
1 day Response (n = 8) – – – – – – – –
STAI 1 week Response (n = 6) – – – – – – – –
Change
(23.8 ± 15.2)
– – – – – – – –
* z>2.3.
** z>2.3 (cluster corrected, p<0.05).
3.3.3. QIDS
Response at 1-day (68.4%), 1-week (63.2%) and 3-weeks (63.2%)
were related to post-treatment increases in amygdala responses for
fearful > neutral faces, again, with greater activations relating to bet-
ter outcomes (Table 1). Response rates at 2-week (57.9%) and 5-week
(47.3%) did not relate to changes in amygdala response.
Furthermore, it can be observed that responders and remitters had
increased amygdala reactivity, while non-responders and non-remit-
ters had decreased amygdala reactivity to fearful > neutral.
3.3.4. Effect of relapse?
Thirteen subjects were responders 1-day after therapy and 9 main-
tained response 5 weeks after therapy. Therefore, we looked at the dif-
ference in the amygdala response between the 4 ‘relapsed’ and the 9
non-relapsed subjects at 5 week and found no differences in amygdala
activation between these sub groups.
4. Discussion
Increased amygdala responses to emotional faces were observed
one day after treatment with psilocybin for treatment-resistant depres-
sion. Post-treatment increases in amygdala responses to fearful versus
neutral faces were related to a successful clinical outcome one week
later.
Importantly, the present findings are in contrast to observations of
decreased amygdala responses after treatment with conventional an-
tidepressants and particularly with SSRIs (1). It has been proposed
that decreased amygdala responsiveness to negative emotional stimuli
under SSRIs is a key component of their therapeutic action (Harmer
et al., 2017), but the present study's findings suggest that this model
does not extend to the therapeutic action of psilocybin for TRD
(Carhart-Harris and Nutt, 2017).
Observations of reduced amygdala responses to negative emo-
tional stimuli (Ma, 2015) and reduced behavioural response biases
to negative stimuli with conventional antidepressants (Harmer et al.,
2009) have been interpreted as evidence of a functional remediation,
linked to the correcting of negative cognitive biases in depression.
However, it is suggested that chronically-used antidepressants have a
more generalised effect on emotional processing, moderating not just
responsiveness to negative emotional stimuli, but emotional stimuli
more broadly (Price et al., 2009). Focusing specifically on the amyg-
dala, this structure is known to be generally sensitive to emotional
salience, regardless of the emotional valence of the stimuli (Adolphs,
2010; Santos et al., 2011). It is possible that the notion that SSRIs have
a selective action on amygdala responses to negative stimuli is fallible,
and rather, SSRIs and related antidepressants have a more generalised
muting influence on amygdala responses to emotionally salient stim-
uli. Relatedly, negative stimuli may be processed as especially salient,
and thus be associated with greater amygdala responses – which are
subsequently hyper-sensitive to intervention-led change.
Reduced amygdala responses to emotional stimuli after chronic an-
tidepressant medication has been linked with activation of post-synap-
tic serotonin 1A receptors (5-HT1ARs), which have an inhibitory ac-
tion on pyramidal cell firing (Andrade, 2011) and are densely ex-
pressed in the amygdala. While this mechanism has a solid empir-
ical basis (Cowen and Browning, 2015; Deakin and Graeff, 1991),
there is no known mechanism to explain how 5-HT1AR-induced at-
tenuation of amygdala responsiveness can selectively apply to nega-
tive stimuli, without simultaneously affecting the processing of pos-
itive stimuli of an equivalent salience. Indeed, there is evidence of
blunting of positive mood with SSRIs (Price et al., 2009). More-
over the relative ineffectiveness of conventional serotonergic antide
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pressant medications to alleviate anhedonia may be explained by a
generalised moderation of emotional responsiveness with these drugs
(McCabe et al., 2010).
We recently carried out a qualitative analysis of patient expe-
riences from this clinical trial, asking patients whether psilocybin
with psychological support has been effective for them, and if so,
how? Since the majority of patients reported improvements with the
treatment, most answered in the affirmative and described a greater
willingness to accept all emotions post-treatment (including negative
ones). These effects were often contrasted with those of their pre-
vious depression treatments which they described as working to re-
inforce emotional avoidance and disconnection (Watts et al., 2017).
Conversely, psilocybin was said to make emotional ‘confrontation’
more likely, and the accompanying psychological support helped pa-
tients achieve an emotional breakthrough (catharsis) and resolution
(Eisner and Cohen, 1958; Gasser et al., 2014b). Consistently, recent
work has suggested that overcoming challenging emotional phenom-
ena under a psychedelic is predictive of better long-term mental health
outcomes (Carbonaro et al., 2016).
It is important to highlight an important discrepancy between the
present results, observed post acutely in patients treated with psilocy-
bin for major depression viewing emotional faces and those from a
previous study in which amygdala responses to emotional stimuli (not
faces) were assessed during the acute psilocybin ‘high’ in healthy in-
dividuals (Kraehenmann et al., 2015). This latter study reported un-
specific decreases in right amygdala responses to negative and neu-
tral stimuli under psilocybin, which, based on the aforementioned sim-
ilarities with the action of conventional antidepressants, the authors
interpreted as supporting an antidepressant action for psilocybin. We
advise caution with this interpretation however, not least because our
pre versus post resting-state fMRI findings suggest that post-acute
changes in spontaneous brain function are very different if not anti-
thetical to psilocybin's acute brain effects (Carhart-Harris et al., 2017).
Moreover, findings of ‘attenuated responses’ with potent interventions
may be explained by compromised task engagement. A consistent ex-
planation has been used to account for apparent functional impair-
ments in imaging studies of pathological states such as schizophrenia,
i.e. impoverished responses are observed because patients do not prop-
erly engage with the task and its stimuli (Corbetta et al., 1990; Rees et
al., 1997).
It is important to acknowledge the limitations of the present study.
It would be interesting to collect longer-term imaging data than the
1-day post treatment scanning point chosen here (e.g. one week and
one month after treatment with psilocybin). If feasible, it would also
be interesting to collect imaging data during the acute experience to
see how this relates to post treatment brain changes. Future work
may look to combine PET and fMRI to systematically address poten-
tial relationships between receptor densities and functional brain mea-
sures before and after treatment with psilocybin. The recruitment of
a healthy control group, receiving the same interventions would also
add value, as would the inclusion of a meaningful comparator condi-
tion such as psilocybin alone versus psilocybin in combination with
psychological support, plus the same for placebo and perhaps an ac-
tive pharmacological control, such as an SSRI and/or methylphenidate
(Griffiths et al., 2006). As this study was not placebo controlled, the
contribution of psilocybin with psychological support cannot be dif-
ferentiated from psychological support and other aspects of the ther-
apy. It would also be worthwhile to see if the present results extend
to a less severe population of depressed patients, including those with
less extensive histories of exposure to psychiatric medication.
Psilocybin represents a novel intervention for major depression
that appears to be safe, rapid and potentially enduring in its antide
pressant action. Furthermore, it is important to note that psilocybin's
abuse potential is low (Johnson and Griffiths, 2017). The original ra-
tionale for using psychedelic (‘mind-revealing’) drugs as aides to psy-
chotherapy was that they serve to dismantle psychological defences,
allowing suppressed emotional material to surface, sometimes with
cathartic effect (Eisner and Cohen, 1958; Gasser et al., 2014b; Grof et
al., 2008). The present findings of increased amygdala responsiveness
post psilocybin resonate with patients' descriptions of feeling emo-
tionally re-connected and accepting after the treatment (Watts et al.,
2017). The finding of a relationship between increased right amygdala
responses to fearful > neutral faces post treatment and subsequent clin-
ical improvements adds further endorsement to this interpretation. Fu-
ture work is required to test the replicability of these findings and test
whether enhanced amygdala responsiveness is related to the poten-
tially enduring positive mood effects of psychedelics (Griffiths et al.,
2006; Schmid and Liechti, 2017). If confirmed, this would suggest an
alternative neurobiological basis to the alleviation of depressive symp-
toms distinct from that of the SSRI antidepressants (Carhart-Harris
and Nutt, 2017).
““I felt so much lighter, like something had been released, it was
an emotional purging, the weight and anxiety and depression had
been lifted.”
““I have felt a sense of acceptance; more acceptance of agony,
boredom, loneliness. [A] willingness to try to accept the negative
times - but also an appreciation of the wonderful times.”
(Two patients’ testimonies from recent psilocybin for TRD trial)
(Carhart-Harris et al., 2016; Watts et al., 2017).
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